At the inception of the response (day 4.5), M002 treatment drove a much higher level of T-bet (MFI, 1752), the transcription factor for TH1 subset, in tumor-infiltrating effector Foxp3− CD4+ T cells, which was increased over 3-fold in comparison to saline treatment (MFI, 505) in mice bearing GSC005 tumors (Fig. 4a). Here, FOXP3 is linked to neoplasm.